T1	Participants 246 261	cancer patients
T2	Participants 473 529	patients undergoing therapy with neurotoxic chemotherapy
T3	Participants 939 965	Two-hundred seven patients
T4	Participants 1038 1070	189 evaluable cases for analysis
